UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
August 8, 2003
--------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
---------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
-------- --------- ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue Northvale, New Jersey 07647
---------------------------------------------
(Address of principal executive offices)
201 750-2646
------------
(Registrant's telephone number, including area code)
Item 5. Other Events and Regulation FD Disclosure
On August 8, 2003, Registrant issued a press release
disclosing that its Board of Directors has authorized its officers to
negotiate a merger agreement with Nostrum Pharmaceuticals Inc., a
privately-held developer of drug delivery products ("Nostrum") to
provide for the acquisition of Nostrum in exchange for shares of
Registrant's Common Stock and options to acquire additional shares of
Registrant's Common Stock. See Item 7(c). No assurance can be given
that any agreement will be executed or, if executed, that any
transaction will result therefor.
Item 7. Financial Statements and Exhibits
a) Not applicable.
b) Not applicable.
c) Exhibits.
Exhibit No. Document Description
----------- --------------------
99.1 Copy of Press Release dated August 8, 2003
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DATED: AUGUST 8, 2003
ELITE PHARMACEUTICALS, INC.
By: /s/ Mark Gittelman
-------------------------------------
Name: Mark Gittelman
Title: Chief Financial Officer